Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel antisense RNA transcript to calcium voltage-gated channel auxiliary subunit alpha2delta 3 (CACNA2D3-AS)
- Target
- CACNA2D3-AS
- Molecular classification
- Other (Antisense RNA transcript), Non-coding RNA
01
Overview
CACNA2D3 antisense transcript (ENSG00000286353) is a non-coding RNA molecule transcribed from the region antisense to the CACNA2D3 gene, which encodes a regulatory subunit of voltage-gated calcium channels. Antisense transcripts can modulate expression of their associated sense genes through epigenetic modifications, alteration of chromatin structure, or direct RNA interference. The specific biological function and disease relevance of this transcript are currently unknown; it is not considered a classical therapeutic target, but its general category (antisense RNA) has emerging importance in drug discovery and biomarker research[2][4][6].
- Other names
- CACNA2D3 antisense RNACACNA2D3-AS (generic antisense nomenclature)ENSG00000286353 (Ensembl ID)
02
Mechanism of action
Not established. For antisense RNAs that are targeted by drugs, mechanisms may include *modulation of gene expression* through RNA interference, blocking transcription, or altering chromatin state[4].
03
Biological functions
Regulation of gene expression (e.g., modulation of sense CACNA2D3 transcript levels, possibly via epigenetic mechanisms or RNA interference)[2][4]Chromatin modification (associated with changes in histone acetylation and transcriptional activity)[2]Other (Role likely context-dependent; specific functions for this transcript are not characterized in the literature)
04
Disease associations
Other (No documented direct disease associations for this specific transcript; however, antisense RNAs in general have been implicated in various diseases such as cancer and neurodegeneration[4])Potential indirect relevance to cancer (since CACNA2D3 methylation is a biomarker in cancer[1], antisense regulation could play a role, but direct evidence for this transcript is lacking)
Beyond the preview
Go deeper on Novel antisense RNA transcript to calcium voltage-gated channel auxiliary subunit alpha2delta 3 (CACNA2D3-AS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel antisense RNA transcript to calcium voltage-gated channel auxiliary subunit alpha2delta 3 (CACNA2D3-AS).